77 - Therapeutic Controversy

Debate Style Speaker(s)

• 

  Jessica Allegretti, MD,MPH

  Associate Director, Crohn's and Colitis Center
  Brigham and Women's Hospital
  Cambridge, Massachusetts

  Disclosure: Artugen : Consultant (Status: Ongoing); Finch Therapeutics : Consultant (Status: Ongoing); Merck : Grant/Research Support (Status: Ongoing)
• 

  Kevin Garey, MS;PharmD

  Professor and Chair
  Pharmacy Practice and Translational Research
  University of Houston College of Pharmacy
  Houston, TX

  Disclosure: Acurx Pharmaceuticals : Research Grant or Support (Status: Ongoing); Summit pharmaceuticals : Research Grant or Support (Status: Ongoing)
• 

  David Paterson, MD, PhD

  Director, UQCCR
  The University of Queensland, Queensland, Australia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Jesús Rodríguez-Baño, PhD MD

  Head, Infectious Diseases Division
  Hospital Universitario Virgen Macarena
  Gelves Sevilla, Spain

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Learning Objectives:

• appraise contemporary literature on the optimal treatment of ESBL infections
• describe treatment options for severe C. diff infections

Presentations:

• 11:30am – 12:45pm EDT

  BL/BLI for ESBL Producers – a Bad Idea
  David Paterson, MD, PhD – The University of Queensland
• 11:30am – 12:45pm EDT

  BL/BLI for ESBL Producers – Not Dead Yet
  Jesús Rodríguez-Baño, PhD MD – Hospital Universitario Virgen Macarena
• 11:30am – 12:45pm EDT

  Management of Severe C. Diff Infections – FMT
  Jessica R. Allegretti, MD,MPH – Brigham and Women's Hospital
• 11:30am – 12:45pm EDT

  Management of Severe C. Diff Infections – Pharmacotherapy
  Kevin W. Garey, MS;PharmD – University of Houston College of Pharmacy